PUC frequently exhibits alterations in the p53, RB, and DNA damage repair pathways, in addition to a high tumor mutation burden and immune-infiltrated phenotype [73], suggesting its potential responsiveness to ICIs such as pembrolizumab and atezolizumab. Here, RB1 is linked to neoplasm.